contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  createdAt
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
    forum {
      threadUrl
    }
    defaultInstrument {
      symbol
      id
    }
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        threadUrl
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        symbol
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
      researchContent {
        title
        lang
        pdfUrl
        relatedContent {
          __typename
          ...PublishingDetails
          ...Reactions
          id
        }
        content {
          title
          lang
          htmlBody
          publishedAt
          createdAt
          changedAt
          isOutdated
          isPremium
        }
      }
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


redeye-chromogenics-entering-2024-with-the-ambitious-skanska-collaboration-in-focus

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

ChromoGenics AB Rights Issue. Let’s see how that’s subscribed, I don’t think I’ll be funding it anymore, I’ve done my share/taken my losses.

I wouldn’t say it’s a scam, but rather that the company is in deep trouble. At least the things I’ve mentioned can be read in the company’s own publications. Bankruptcy risk isn’t shouted from the rooftops, but I was able to get a picture of the situation in less than fifteen minutes. I don’t see many reasons why an outsider would buy this company. By buying the estate through bankruptcy, one gets rid of the warranty liabilities this company has, which could still lead to compensation claims based on past performance. Due to the bankruptcy risk, the sales pipeline might be blocked because customers inevitably face uncertainty about whether they will receive their products, and even if they did, would the warranty period even matter? Rarely has any company’s situation screamed “don’t buy” as loudly as this one. But of course, do your own review of the numbers, etc.!

So, could this even be called a deliberate scam?

I looked through the 2022 figures and concluded that at a burn rate of 10-15 MSEK/quarter, the company will run out of money by the end of the year. Production difficulties, material waste, and the CFO is resigning. The ESG card is being played, but it still smells like bankruptcy to me. It’s no wonder, then, that the AGM has been postponed until the summer “for practical reasons”. They need to scrape together some money from somewhere quickly to appease the auditor.

The wait has been long. Well, at least something seems to be happening. There is likely a demand for the product in the Middle Eastern market. Let’s wait for the trade announcements: ChromoGenics enters cooperation with Future Glass, UAE ChromoGenics and Future Architectural Glass LLC (Future Glass) of UAE have signed a letter of intent regarding manufacturing, marketing and distribution of the dynamic glass ConverLight® Dynamic. Future Glass is a highly respected supplier & integrator of advanced architectural glass & glazing solutions in the Middle East with a proven track record of 500+ projects across 35+ countries world-wide. Since 1976, the group has been serving the needs of the architectural glass & glazing market by providing the latest technologies & solutions suiting the dynamic needs of developers, architects, consultants & contractors. The company has positioned itself as a premium glass fabricator based in the Middle East having the entire gamut of European machinery and systems to process any type of architectural glass. Services include safety glass manufacturing, curved and laminated glass as well as other specialty glass solutions. Future Glass will in due course laminate ConverLight ® Dynamic foil into finished glass solutions. Future Glass has extensive experience of sales and marketing of specialized glass solutions and strong market knowledge, with sales to over 35 countries including the USA, UK and Europe. ‘We look forward to developing this innovative product together with ChromoGenics. We see a substantial opportunity in the market. The opportunity to manufacture dynamic glass in our own factory, using ChromoGenics technology, is very attractive to us’ said Firoz Kachwala, Executive Director, Future Architectural Glass. ‘We are very pleased to start our cooperation with Future Glass. We are impressed with their technical competence, scale, and quality of manufacturing as well as their deep experience of selling advanced glass solutions including dynamic glass. The Middle East is a very interesting market for us, where Future Glass is a sizeable and well-respected company. We look forward to developing this and other markets together with their competent team’ says Fredrik Fränding, CEO of ChromoGenics. Contact:  Fredrik Fränding, CEO  Tel: +46 (0) 18 430 0430  E-mail: info@chromogenics.com  ChromoGenics Future Glass  Firoz Kachwala, Executive Director  K R Ananthanarayanan, Business Development Manager – UK & Europe  Cellular : +44 7537 188799  E-Mail : ananth@faglass.com  https://faglass.com

Redeye initiated coverage, the report is freely available:            s3-eu-west-1.amazonaws.com              initialanalys-chromogenics_final.pdf    2.10 MB

Hopefully, this isn’t the only project; more are needed now that the price has dropped to roughly one-hundredth of what it was. For me, 10-baggers won’t be enough here

ChromoGenics

Redeye provides an update on ChromoGenics following the company's Q4 2023 results. A weak quarter closed a tough 2023. But with recent successful capital increase, and a few good projects in...

<div class="mfn-body"><p>Redeye provides an update on ChromoGenics following the company's Q4 2023 results. A weak quarter closed a tough 2023. But with recent successful capital increase, and a few good projects in the pipeline, 2024 looks promising.</p><p><a rel="noopener" href="https://www.redeye.se/research/969968/chromogenics-entering-2024-with-the-ambitious-skanska-collaboration-in-focus?utm_source=MFN&amp;utm_medium=pmcour">Read more and download the Research Update.</a><br>&nbsp;<br>Follow companies at Redeye to receive the latest equity research within Life Science and Technology.<br>&nbsp;<br>This is a press release from Redeye - Research Powered Investment Banking. <a rel="noopener" href="https://www.redeye.se/">www.redeye.se/</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/ea5f6d20-193c-4420-a321-f7be24ea22eb/chromogenics-entering-2024-with-the-ambitious-skanska-collaboration-in-focus.pdf" class="mfn-generated mfn-primary">ChromoGenics - Entering 2024 with the ambitious Skanska collaboration in focus</a></p></div>

Redeye: ChromoGenics - Entering 2024 with the ambitious Skanska collaboration in focus

Redeye: ChromoGenics - Entering 2024 with the ambitious Skanska collaboration in focus